Ground-breaking X-ZELL research featured in BJU International
Oxford, August 2018 – X-ZELL Inc. CEO, Dr Sebastian Bhakdi, has published new research into the utility of tumour-derived Circulating Endothelial Cells (tCEC) for the detection of early-stage prostate cancer.
His latest abstract – titled Tumor‐Derived Circulating Endothelial Cells Predict Clinically Significant Prostate Carcinoma (#57) – was selected for the August edition of BJU International, the official journal of the British Association of Urological Surgeons, and outlines how X-ZELL’s blood-based tCEC detection test can prevent more than 70 per cent of unnecessary invasive procedures in patients with elevated PSA levels or an abnormal digital rectal examination (DRE) result.
All that is needed to perform the test is a small, 10ml blood sample, according to Dr Bhakdi, as well as a suite of patented technologies developed by X-ZELL Inc.
Dr Bhakdi’s abstract is based on a pilot study covering 150 patients with inconclusive screenings results that was carried out in close collaboration with Mahidol University and Siriraj Hospital in Bangkok, Thailand over the first half of 2018. It was first presented at the Asia-Pacific Prostate Cancer Conference in Brisbane, Australia last month.
The full text as well as the corresponding scientific poster are now available online, with additional details to be revealed at an official press conference in Bangkok next month. Details on the event are yet to be confirmed. If you wish to attend, please email us on email@example.com.
About X-ZELL Prostate™
X-ZELL Prostate™ is a liquid biopsy test using tumor-derived circulating cells, including tumor-derived Circulating Endothelial Cells (CEC), as biomarkers to indicate the presence/ absence of clinically significant prostate cancer in small, 8-10mL blood samples. Click here to find out more.